Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: A management dilemma

Pharmacotherapy

Volumn 32, Issue 1, 2012, Pages

  Pau, Alice K ^a   Penzak, Scott R ^b   Boyd, Sarita D ^c   McLaughlin, Mary ^a   Morse, Caryn G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

HIV; Human immunodeficiency virus; Liver failure; Maraviroc; Pharmacokinetics; Raltegravir; Renal failure; TDM; Therapeutic drug monitoring

Indexed keywords

ENFUVIRTIDE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR;

ACUTE LIVER FAILURE; ADULT; ANEMIA; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTUSSUSCEPTION; KIDNEY DYSFUNCTION; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER FAILURE; MALE; PNEUMOCOCCAL INFECTION; THROMBOCYTOPENIA;

ADULT; CYCLOHEXANES; DISEASE MANAGEMENT; END STAGE LIVER DISEASE; FATAL OUTCOME; HIV INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRROLIDINONES; RENAL INSUFFICIENCY; TRIAZOLES;

EID: 84860710732     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1003     Document Type: Article

References (18)

1. Pfizer Inc. Selzentry (maraviroc) package insert. New York, NY; 2010.
2. Merck & Co., Inc. Isentress (raltegravir) package insert. Whitehouse Station, NJ; 2011.
3. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-15. (Pubitemid 44885615)
4. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009;14:607-18.
5. Jackson A, D'Avolio A, Watson V, et al. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid lowering drug ezetimibe in healthy volunteers. J Antimicrob Chemother 2011;66:885-9.
6. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010;24:1537-48.
7. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377:1198-209.
8. French National Agency for Research on AIDS and Viral Hepatitis. Raltegravir in patients with end stage liver disease and in transplant recipients (LIVERAL). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http:// clinicaltrials.gov/ct2/show/NCT01022476?term= NCT01022476&rank=1. Accessed July 28, 2011.
9. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Pharmacokinetic study of raltegravir in human immunodeficiency virus/hepatitis C virus (HIV/ VHC) coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis (LIVERAL). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials. gov/ct2/show/ NCT01289951?term=NCT01289951&rank=1. Accessed July 28, 2011.
10. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(suppl 1):60-7. (Pubitemid 351366540)
11. Abel S, van der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteer. Br J Clin Pharmcol 2008;65(suppl 1):5-18. (Pubitemid 351366533)
12. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-9.
13. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment- experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9. (Pubitemid 46553846)
14. Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 2009;53:1747-52.
15. Tommasi C, Nicastri E, Gallo AL, et al. Raltegravir and darunavir plasma pharmacokinetic in HIV-1 infected patients with advanced liver disease [abstract]. Presented at the 11th international workshop on clinical pharmacology and HIV therapy, Sorrento, Italy, April 7-9, 2010; abstract 10.
16. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7.
17. Baroncelli S, Villani P, Weimer LE, et al. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother 2010;44:838-43.
18. Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010;69:51-7.